HYFTOR

This brand name is authorized in United States. It is also authorized in Austria, Estonia, Ireland, Italy, Lithuania.

Active ingredients

The drug HYFTOR contains one active pharmaceutical ingredient (API):

1	Sirolimus UNII W36ZG6FT64 - SIROLIMUS
	Sirolimus inhibits T-cell activation induced by most stimuli, by blocking calcium-dependent and calcium-independent intracellular signal transduction. Studies demonstrated that its effects are mediated by a mechanism that is different from that of ciclosporin, tacrolimus, and other immunosuppressive agents.
	Read more about Sirolimus

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
HYFTOR Gel	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AH01	Sirolimus	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors
Discover more medicines within L04AH01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3044876
IT	Agenzia del Farmaco	050701010
LT	Valstybinė vaistų kontrolės tarnyba	1097168
US	FDA, National Drug Code	73683-101